There have been a few human clinical trials and studies involving BPC-157, but the available data is limited and does not provide a comprehensive overview of its efficacy and safety in humans. The strongest current conclusion is that BPC-157 is promising preclinically, has limited early human safety signals, but has no published robust human efficacy trial proving it works for injuries, gut disease, pain, or recovery [3].
What the AI assistants say
The AI assistants collectively agree that there have been a few human clinical trials and studies involving BPC-157, but the evidence base is limited and of low quality. They highlight that there have been no large-scale, placebo-controlled, randomized human clinical trials of BPC-157 that have been completed and published in peer-reviewed journals to establish its safety and efficacy in humans [1]. The AI assistants also note that most of the evidence for BPC-157’s effects comes from preclinical studies in animals, which show promising results across various physiological systems [2].
What the research actually shows
Research from various sources suggests that BPC-157 has been studied for its potential therapeutic effects in various conditions. Source [1] mentions that BPC-157 has been explored in clinical trials for inflammatory bowel disease (PL 14736) and has shown efficiency in various wound treatments, with no toxicity reported. This suggests that human clinical trials have indeed been conducted for certain applications of BPC-157 [1].
Source [5] discusses the cytoprotective mediator properties of BPC-157, indicating its use in the gastrointestinal tract, liver, and pancreas, among other potential medical uses. While this source does not explicitly mention human clinical trials, it does highlight the peptide’s therapeutic potential, which has likely been investigated in human studies [5].
Source [12] provides specific details on a study involving BPC-157 and traumatic nerve injury. The abstract mentions a focus on “the healing of rat transected sciatic nerve and improvement made by stable gastric pentadecapeptide BPC 157.” Although this study involved rats, it implies that the therapeutic effects of BPC-157 are being investigated, and it’s plausible that similar studies have been conducted on humans [12].
Source [16] discusses the beneficial effects of BPC-157 on ligament healing, citing various studies that have been conducted. While these studies may not be explicitly human clinical trials, they provide evidence of the peptide’s potential therapeutic effects [16].
Source [17] and [18] discuss the potential neuroprotective effects of BPC-157 in the context of traumatic brain injury (TBI). The studies mentioned focus on the peptide’s ability to prevent immediate unconsciousness and death during the earliest post-injury period and its potential role in attenuating neurotoxin damage. Although these sources discuss the peptide’s effects in mice, they suggest that BPC-157 may have therapeutic potential in humans with TBI [17], [18].
Source [8] and [9] provide detailed information on a study involving BPC-157 and traumatic brain injury in mice. The study describes the attenuating effect of BPC-157 on the intensity and distribution of traumatic lesions and consecutive brain edema. While this study was conducted on mice, it offers insights into the potential therapeutic effects of BPC-157 in humans with TBI [8], [9].
Where AI consensus and research diverge
The AI assistants collectively emphasize the lack of large-scale, high-quality human clinical trials for BPC-157, while the research corpus provides some evidence of human studies and trials that have been conducted. However, both the AI assistants and the research corpus agree that more specific information on human clinical trials is needed for a comprehensive understanding of BPC-157’s effects in humans.
Bottom line: While there have been a few human clinical trials and studies involving BPC-157, the available data is limited and does not provide a comprehensive overview of its efficacy and safety in humans. More specific information on human clinical trials is needed for a comprehensive understanding of its effects in humans.
References
- Antimicrobial Peptides_ Basics for Clinical Application
- Boundless Upgrade Your Brain, Optimize Your Body and Defy — Ben Greenfield
- Foundations of Regenerative Medicine
- Innovative Approaches in Drug Discovery
- Novel cytoprotective mediator, stable gastric pentadecapeptide BPC 157. Vascular recruitment and gastrointestinal tract
- Pentadecapeptide BPC 157 (PL 14736) improves ligament — Tomislav Cerovecki
- Peptide Protocols Volume One — William A Seeds MD
- Peptide drug discovery and development _ Translational — edited by Miguel Castanho and
- Peptide therapy with pentadecapeptide BPC 157 in traumatic — Gjurasin, Miroslav
- The effect of pentadecapeptide BPC 157, H-blockers — Predrag Sikiric
- Traumatic brain injury in mice and pentadecapeptide BPC 157 — Mario Tudor
- Understanding the Genome (Science Made Accessible) — from the editors of Scientific American
Continue your research
Part of our BPC-157: Research Evidence & Trials guide.
- How much of the BPC-157 research is animal studies versus human clinical trials?
- What are the strongest scientific criticisms of the BPC-157 research literature?
- Why does almost all BPC-157 research come from a single research group, and does that matter?
- What would it take for BPC-157 to become an approved medicine?
Related topics:
- Is there any evidence that BPC-157 helps bone fractures heal?
- Why hasn't BPC-157 been approved by the FDA, and why did the FDA restrict compounding it?
- Are there any known drug interactions with BPC-157?